5 Crescent Drive
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2807 articles with GlaxoSmithKline
Nicorette and Dale Earnhardt Jr. Launch New Nicorette Coated Ice Mint Lozenges to Help Smokers Succeed on Their Quest to Quit
Former Smoker and Racing Legend Teams Up with America's #1 Smoking Cessation Brand to Offer Taste Test Drives So Smokers Can Put the Brakes on Their Cravings
Expands global footprint for complex API manufacturing
Vectura Group plc confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s Ellipta products.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipta (FF/VI), in the treatment of patients living with uncontrolled asthma.
In its announcement, GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine.
Crown Laboratories Acquires Keri® From GlaxoSmithKline And Receives An Equity Investment From Greenspring Associates
Crown Laboratories, Inc. ("Crown"), a leading, fully integrated skin care company, today announced it has acquired the North American rights for Keri® from GlaxoSmithKline ("GSK") and received an equity investment from Greenspring Associates, Inc. ("Greenspring").
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
4/25/2019The funding will be used to expand the production capacity of key components of the adjuvant system used in several of GSK's vaccines, including shingles vaccine, Shingrix.
Site expansion will boost vaccine production capacity
Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.
Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy
Fulcrum plans to launch a Phase 2b clinical trial in FSHD in mid-2019
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
Since GSK initiated this new focus, the company has made several key moves to support the plan, including the December 2018 acquisition of Tesaro Oncology.
The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Dovato, a once-a-day, single-tablet combination of dolutegravir (DTG) and lamivudine (3TC) for HIV-1 in adults who had not received treatment before.
The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.